Private Advisor Group LLC increased its position in Amarin Co. plc (NASDAQ:AMRN) by 17.8% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 79,735 shares of the biopharmaceutical company’s stock after purchasing an additional 12,049 shares during the period. Private Advisor Group LLC’s holdings in Amarin were worth $1,297,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of AMRN. Signature Estate & Investment Advisors LLC acquired a new position in Amarin in the third quarter valued at approximately $137,000. BKS Advisors LLC acquired a new position in Amarin in the third quarter valued at approximately $162,000. Northern Trust Corp boosted its stake in Amarin by 20.9% in the second quarter. Northern Trust Corp now owns 113,327 shares of the biopharmaceutical company’s stock valued at $350,000 after acquiring an additional 19,590 shares during the period. TD Asset Management Inc. boosted its stake in Amarin by 54.4% in the second quarter. TD Asset Management Inc. now owns 134,207 shares of the biopharmaceutical company’s stock valued at $415,000 after acquiring an additional 47,300 shares during the period. Finally, GSA Capital Partners LLP boosted its stake in Amarin by 66.3% in the second quarter. GSA Capital Partners LLP now owns 162,800 shares of the biopharmaceutical company’s stock valued at $503,000 after acquiring an additional 64,900 shares during the period. Institutional investors and hedge funds own 39.86% of the company’s stock.

In other news, insider Steven B. Ketchum sold 879,241 shares of Amarin stock in a transaction that occurred on Tuesday, September 25th. The stock was sold at an average price of $11.10, for a total transaction of $9,759,575.10. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, General Counsel Joseph T. Kennedy sold 1,079,706 shares of Amarin stock in a transaction that occurred on Monday, September 24th. The shares were sold at an average price of $10.56, for a total value of $11,401,695.36. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 3,623,760 shares of company stock worth $46,399,759. Corporate insiders own 4.08% of the company’s stock.

A number of brokerages have commented on AMRN. BidaskClub downgraded Amarin from a “hold” rating to a “sell” rating in a research note on Thursday. HC Wainwright restated a “buy” rating and issued a $51.00 target price (up from $31.00) on shares of Amarin in a research note on Monday. SunTrust Banks lifted their target price on Amarin to $30.00 and gave the company a “reduce” rating in a research note on Monday, November 5th. Citigroup downgraded Amarin from a “buy” rating to a “neutral” rating and lifted their target price for the company from $25.00 to $28.00 in a research note on Friday, November 2nd. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $35.00 target price on shares of Amarin in a research note on Thursday, November 1st. Two analysts have rated the stock with a sell rating, two have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $31.80.

AMRN opened at $17.72 on Friday. Amarin Co. plc has a twelve month low of $2.35 and a twelve month high of $23.33.

Amarin (NASDAQ:AMRN) last released its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.09) by $0.01. The business had revenue of $55.00 million for the quarter, compared to the consensus estimate of $60.63 million. The business’s quarterly revenue was up 16.8% on a year-over-year basis. During the same period last year, the firm posted ($0.04) EPS. On average, equities analysts anticipate that Amarin Co. plc will post -0.34 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This article was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://www.thecerbatgem.com/2018/11/16/private-advisor-group-llc-boosts-position-in-amarin-co-plc-amrn.html.

Amarin Profile

Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.

See Also: How a Put Option Works

Want to see what other hedge funds are holding AMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amarin Co. plc (NASDAQ:AMRN).

Institutional Ownership by Quarter for Amarin (NASDAQ:AMRN)

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.